Katrine Bosley's new job

Hey, things happened yesterday beyond the STAT Summit! Katrine Bosley, former Editas chief executive, climbed aboard as chairman of the board of Arrakis Therapeutics. 

The company, led by serial bio-entrepreneur Michael Gilman, takes a small molecule approach to RNA. Its compounds aim at binding to, and then modifying the function of, RNA. Most small molecules, by contrast, target proteins that are formed by RNA. The Arrakis approach is meant to work a little earlier in the disease process. It’s raised more than $100 million in venture funding to date.